TIMI 5

OBJECTIVE: To evaluate the safety and efficacy of several doses of hirudin vs. unfractionated heparin in combination with front-loaded tPA for the treatment of patients presenting with ST elevation myocardial infarction.

View/Download
_______________________________________________________________________________

1. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. Cannon CP, McCabe CH, Henry TD, et al. J Am Coll Cardiol 1994;23:993-1003.
   | Abstract | Request Reprint |
   
   

2. Comparative effects of heparin and hirudin on fibrinolytic and thrombotic activities during tissue type plasminogen activator therapy. Loscalzo J, Abdenschein D, Eisenberg P, Becker R, George D, McCabe C, Sobel B, Braunwald E, for the TIMI 5 Investigators. Circulation 1993;88.
   | Request Reprint |
   
   
3. Culprit lesion changes in acute myocardial infarction: a TIMI 5 comparison of patients treated with t-PA and either heparin or hirudin.Sharaf BL, Miele N, Ferreira P, McKendall GR, Williams DO. J Am Coll Cardiol 1993;21:419A.
   | Request Reprint |
   
   
4. Natural history of serial intrahospital quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction. Wackers FJT, Cannon CP, McMahon M, Zaret BL, and TIMI Investigators. J Am Coll Cardiol 1993;21 (Suppl. A):249A.
   | Request Reprint |
   
   
5. Usefulness of APTT to predict bleeding for hirudin (and heparin). Cannon CP, Becker RC, Loscalzo J, Gallo P, Henis M, Edwards SJ, McCabe CH, Braunwald E, for the TIMI 5 Investigators. Circulation 1994;90[Pt. 2]:I-563.
   | Request Reprint |
   
   
6. Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department. Boisjolie CR, Sharkey SW, Cannon CP, et al. Am J Cardiol 1995;76:396-8.
   | Abstract | Request Reprint |
   
   
7. Toward establishing anticoagulation guidelines for intravenous heparin administration among patients with myocardial infarction given tissue plasminogen activator. Becker RC, Cannon CP, George D, Loscalzo J, for the TIMI 5 Investigators. J Am Coll Cardiol 1995;Special Issue:309A.
   | Request Reprint |
   
   
8. Is there a circadian variation in anticoagulant response to hirudin following acute myocardial infarction? Henry TD, Becker RC, Cannon CP, McCabe CH, Loscalzo J, for the TIMI 5 Investigators. J Am Coll Cardiol 1995;Special issue:310A.
   | Request Reprint |
   
   
9. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Scharfstein JS,Abendschein DR, Eisenberg PR, et al. Am J Cardiol 1996;78:503-10.
   | Abstract | Request Reprint |
   
   
10. A composite and practical view of standard coagulation monitoring in the identification of patients at risk for major hemorrhage. Becker RC, Cannon CP, Ma Y, Hurley T, Hebert J. J Am Coll Cardiol 1996;27 (Suppl. A):81A-82A.
    | Request Reprint |
    
    
11. Early aPTT measurement are not a surrogate for in vivo thrombin inhibition among patients receiving thrombolytic therapy and adjunctive anticoagulation. Becker RC, Hebert J, Hurley T, Ma Y, Cannon CP, for the TIMI 5 Hemostasis and Thrombosis Study Group. J Am Coll Cardiol 1996;27(Suppl. A):11A-12A.
    | Request Reprint |